RGNT
Regentis Biomaterials
$1.96
−$0.05 (−2.49%)Sep 10, 2026
Key metrics
The numbers that frame RGNT today
- Market cap
- $10.15M
- P/E (TTM)
- -0.7
- EV / FCF
- -2.9
- ROIC
- 1,188.3%
- Div yield
- 0%
- Debt / equity
- 0.3
Growth
Revenue and earnings trend for RGNT
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RGNT
Is Regentis Biomaterials a good buy?
No. Regentis Biomaterials has poor quality. We think Regentis Biomaterials is selling at a very high price.
What is the market capitalization of RGNT?
Regentis Biomaterials's market capitalization is $10.15M.
What is the P/E ratio for RGNT stock?
Regentis Biomaterials's current P/E ratio is -0.7.
Does RGNT stock pay dividends?
Regentis Biomaterials does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RGNT?
Regentis Biomaterials's Debt / Equity ratio is 0.25.